NeuroOne Medical Technologies Files Definitive Proxy Statement

TL;DR

NEUR proxy statement filed. Shareholders vote on directors, exec pay, etc. Jan 21, 2025.

AI Summary

NeuroOne Medical Technologies Corp. filed its definitive proxy statement on January 21, 2025, for its annual meeting of stockholders. The filing, designated as DEF 14A, outlines the company's governance and proposals to be voted on by shareholders. Key details regarding executive compensation, director elections, and other corporate matters are expected to be detailed within the full proxy statement.

Why It Matters

This filing provides shareholders with crucial information about the company's leadership, executive compensation, and upcoming voting matters, enabling informed participation in corporate governance.

Risk Assessment

Risk Level: medium — Proxy statements can reveal information about executive compensation, board composition, and shareholder proposals that may indicate potential governance risks or strategic shifts.

Key Numbers

• 20250121 — Filing Date (The date the definitive proxy statement was filed with the SEC.)
• 20250214 — Period of Report (The fiscal period the proxy statement pertains to.)

Key Players & Entities

• NEUROONE MEDICAL TECHNOLOGIES Corp (company) — Registrant
• 0001213900-25-005016 (filing_id) — Accession Number
• 20250121 (date) — Filing Date
• 20250214 (date) — Period of Report
• 001-40439 (company_id) — SEC File Number

FAQ

Key Financial Figures

• $0.001 — he Company's common stock, par value of $0.001 per share (the "Common Stock"), at the
• $80 million — . Buckman founded and developed into an $80 million business, from January 2001 to January
• $50,000 — directors receive an annual retainer of $50,000, except that our non -executive chairma
• $100,000 — chairman receives an annual retainer of $100,000. Additionally, the chairman and members
• $17,000 — receive an additional annual payment of $17,000 and $9,000, respectively, the chairman
• $9,000 — dditional annual payment of $17,000 and $9,000, respectively, the chairman and members
• $10,000 — receive an additional annual payment of $10,000 and $6,000, respectively, and the chair
• $6,000 — dditional annual payment of $10,000 and $6,000, respectively, and the chairman and mem
• $5,000 — dditional annual payment of $10,000 and $5,000, respectively. The non -employee direc
• $12,500 — receive an additional annual payment of $12,500 and $5,000, respectively, and the chair
• $4,000 — dditional annual payment of $10,000 and $4,000, respectively. 6 Table of Contents

Filing Documents

• ea0227444-02.htm (DEF 14A) — 1429KB
• tbarchart_001.jpg (GRAPHIC) — 281KB
• tbarchart_002.jpg (GRAPHIC) — 322KB
• tneuro_logo.jpg (GRAPHIC) — 35KB
• tproxy_001.jpg (GRAPHIC) — 1167KB
• tproxy_002.jpg (GRAPHIC) — 1128KB
• 0001213900-25-005016.txt ( ) — 9195KB
• nmtc-20250106.xsd (EX-101.SCH) — 13KB
• nmtc-20250106_def.xml (EX-101.DEF) — 9KB
• nmtc-20250106_lab.xml (EX-101.LAB) — 44KB
• nmtc-20250106_pre.xml (EX-101.PRE) — 11KB
• ea0227444-02_htm.xml (XML) — 333KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 31 EXECUTIVE OFFICERS 33

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 35 PAY VERSUS PERFORMANCE 43 CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS 46 ADDITIONAL INFORMATION 47 OTHER MATTERS 50 APPENDIX A A-1 APPENDIX B B-1 i Table of Contents NEUROONE MEDICAL TECHNOLOGIES CORPORATION PROXY STATEMENT FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS GENERAL INFORMATION ABOUT THE ANNUAL MEETING Our Board of Directors (the "Board") solicits your proxy on our behalf for the 2025 Annual Meeting of Stockholders (the "Annual Meeting") and at any postponement or adjournment of the Annual Meeting for the purposes set forth in this proxy statement (the "Proxy Statement") and the accompanying Notice of 2025 Annual Meeting of Stockholders (the "Notice"). The Annual Meeting will be held at our principal executive offices at 7599 Anagram Dr., Eden Prairie, MN 55344, on Thursday, February 14, 2025 at 9:00 a.m. local time. This Proxy Statement is first being sent to stockholders on or about January 21, 2025. We currently intend to hold the Annual Meeting in person. However, in the event we determine it is not possible or advisable to hold the Annual Meeting in person, we will publicly announce alternative arrangements for the Annual Meeting as promptly as practicable before the Annual Meeting. Please monitor our website at www.nmtc1.com for updated information. Unless we state otherwise or the context otherwise requires, references in this Proxy Statement to "we," "our," "us," or the "Company" are to NeuroOne Medical Technologies Corporation, a Delaware corporation. Purpose of the Annual Meeting At the Annual Meeting, stockholders will act upon the proposals described in this Proxy Statement. In addition, we will consider any other matters that are properly presented for a vote at the Annual Meeting. We are not aware of any other matters to be submitted for consideration at the Annual Meeting. If any other matters are properly presented for a vote at the Annual Meeting, the persons named in the

View Full Filing

View this DEF 14A filing on SEC EDGAR